Kuros Biosciences 9M 2026 EBITDA jumps 81% to USD 13.5 million
Kuros Biosciences’ Group EBITDA jumped 81% year-over-year to USD 13.5 million in the first nine months of 2026. Total Medical Device sales climbed 40% year-over-year to USD 141.8 million. Its Alpharetta, Georgia, facility began commercial production of MagnetOs bone graft in October 2026, establishing dual-site manufacturing alongside its Netherlands facility. The group raised its full-year 2026 guidance, now expecting sales growth of 36% to 40%. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kuros Biosciences AG published the original content used to generate this news brief via (Ref. ID: 202610150100PRIMZONEFULLFEED1001277818) on October 15, 2026, and is solely responsible for the information contained therein. (C)
5 million in the first nine months of 2026. 8 million. Its Alpharetta, Georgia, facility began commercial production of MagnetOs bone graft in October 2026, establishing dual-site manufacturing alongside its Netherlands facility. The group raised its full-year 2026 guidance, now expecting sales growth of 36% to 40%.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kuros Biosciences AG published the original content used to generate this news brief via (Ref. ID: 202610150100PRIMZONEFULLFEED1001277818) on October 15, 2026, and is solely responsible for the information contained therein.
(C)